Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma

Sho Ikeda1 | Fumito Abe1 | Yuka Matsuda2 | Akihiro Kitadate1 | Naoto Takahashi1 |  | Hiroyuki Tagawa1

Abstract

Multiple myeloma (MM) is an incurable hematopoietic neoplasm derived from plasma cells, and existing in the bone marrow. Recent developments in the field of myeloma onco-biology have enabled the use of proteasome inhibitors (PIs) as key drugs for MM. PIs can increase cell sensitivity to endoplasmic reticulum stress, leading to apoptosis of myeloma cells. PI cannot kill all myeloma cells, however; one reason of this might be activation of autophagy via hypoxic stress in the bone marrow microenvironment. Hypoxia-inducible gene(s) that regulate autophagy may be novel therapeutic target(s) for PI-resistant myeloma cells. Here, a hypoxia-inducible glycolytic enzyme hexokinase-2 (HK2) was demonstrated to contribute by autophagy activation to the acquisition of an anti-apoptotic phenotype in myeloma cells. We found that hypoxic stress led to autophagy activation accompanied by HK2 upregulation in myeloma cells. Under hypoxic conditions, HK2 knockdown inhibited glycolysis and impaired autophagy, inducing apoptosis. The cooperative effects of a PI (bortezomib) against immunodeficient mice inoculated with HK2-knocked down myeloma cells were examined and significant tumor reduction was observed. An HK2 inhibitor, 3-bromopyruvate (3-BrPA), also induced apoptosis under hypoxic rather than normoxic conditions. Further examination of the cooperative effects between 3-BrPA and bortezomib on myeloma cells revealed a significant increase in apoptotic myeloma cells. These results strongly suggested that HK2 regulates the activation of autophagy in hypoxic myeloma cells. Cooperative treatment using PI against a dominant fraction, and HK2 inhibitor against a minor fraction, adapted to the bone marrow microenvironment, may lead to deeper remission for refractory MM.

Keywords

autophagy, HK2, hypoxia, microenvironment, multiple myeloma

Abbreviations: 3-BrPA, 3-bromopyruvate; BTZ, bortezomib; ER, endoplasmic reticulum; HIF, hypoxia-inducible factor; HK, hexokinase; IL-6, interleukin-6; IRF4, interferon regulatory factor 4; KDM3A, lysine demethylase 3A; MALAT1, metastasis associated in lung adenocarcinoma transcript-1; MM, multiple myeloma; PI, proteasome inhibitor; SQSTM1, sequestosome 1.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1 | INTRODUCTION

Multiple myeloma is a refractory plasma cell tumor that accumulates in the bone marrow. In recent years, the prognosis of MM has improved markedly with the development of various new agents such as immunomodulatory drugs, PIs, and monoclonal antibodies. However, all cases of MM remain incurable because they acquire drug resistance. The drug-resistant fraction of myeloma cells is thought to be protected by multiple factors in the bone marrow microenvironment. These factors are found in 2 compartments in the bone marrow microenvironment: 1 that contains cells and 1 that does not. The former includes blood cells, osteoclasts, osteoblasts, stromal cells, fibroblasts, and vascular endothelial cells, whereas the latter includes the extracellular matrix, hypoxia, starvation, low pH, and soluble factors such as cytokines and growth factors. Among these factors, hypoxic stress in the bone marrow microenvironment is thought to play a crucial role in drug resistance in hematologic malignancies, including MM.

Drug-resistant myeloma cells show an anti-apoptotic phenotype. This phenotype can occur either in normoxia or hypoxia, however the responsible genes are distinct between each condition. Hypoxic stress leads to the induction of distinct gene expression in myeloma cells. For instance, the transcription factor IRF4, which plays crucial roles in acquisition of the anti-apoptotic phenotype of MM, is typically upregulated in MM. However, IRF4, and even its target c-Myc, are downregulated under hypoxic stress. Instead, accumulation of the transcription factor hypoxia-inducible factor-1α (HIF-1α) upregulates anti-apoptotic proteins, increases glycolysis, and enhances neovascularization, leading to the anti-apoptotic phenotype of MM.

Moreover, recent studies have suggested that activation of autophagy is another factor in the acquisition of the anti-apoptotic phenotype of MM. Autophagy is an intracellular process that involves the encapsulation of cytoplasmic components and their targeting to the lysosome for degradation. This process helps cells to survive under nutrient-starved or hypoxic conditions by inducing protein synthesis, removing damaged intracellular organelles, and promoting energy production. This process is also closely related to cancer metabolism and tumor growth. Autophagy may function in an oncogenic or tumor-suppressive manner depending on the type of cancer. In MM, both autophagy activation and proteasomal degradation are thought to contribute to protecting cells from excessive ER stress induced by misfolded proteins.

Based on these findings, we predicted that activation of autophagy in the hypoxic microenvironment increased the resistance capability to apoptosis in MM. This study was conducted to identify factors that induce autophagy in the hypoxic bone marrow microenvironment for use as therapeutic targets for treatment-resistant MM.

2 | MATERIALS AND METHODS

2.1 | Primary MM samples

The study included 6 cases of primary samples from Akita University Hospital (Akita, Japan) and was conducted with written informed consent of the study participants and the approval of the Institutional Review Boards (approval no. 1313), according to the Declaration of Helsinki, before collection of specimens.

2.2 | Myeloma cell lines and culture

Six well known MM cell lines (KMS-12-PE, KMS-11, H929, RPMI-8226, U266, and MM.1S) were used, and obtained from the American Type Culture Collection. A multi-gas incubator MCO-5M-PJ (PHC) was used for hypoxic culture (1% O2). An F-51 (Horiba) apparatus was used to measure the pH of culture media. The method of co-culture with a human stromal cell line HS-5 has been described previously.

2.3 | DNA microarray

Gene expression was analyzed using Agilent DNA microarrays (Agilent) and an Agilent G2600A SureScan Microarray Scanner System. The experiment protocol was in accordance with Agilent Protocol v.6.7. Data were analyzed using GeneSpring software (Agilent), plus computed normalized signal intensity with 75%tile normalization. Data were uploaded to the Gene Expression Omnibus (GEO) database under identification numbers GSE80140 (KMS-11, KMS-12-BM, MM.1S, and RPMI-8226), GSE80545 (patient samples), and GSE96858 (U266).

2.4 | Quantitative reverse transcription-PCR (qRT-PCR) analysis

qRT-PCR was performed using TaqMan methodology (Applied Biosystems). TaqMan probes for GAPDH (Hs02758991_g1), HK1 (Hs00175976_m1), HK2 (Hs00606086_m1), HK3 (Hs001092850_m1), and glucokinase (GCK) (Hs01564555_m1) were purchased from Applied Biosystems. Expression levels were normalized separately against GAPDH and the relative expression levels of specific mRNA were presented as 2−ΔΔC. qRT-PCR was performed using a Light Cycler Nano instrument (Roche). Total RNA was extracted using TRizol reagent (Life Technologies). Reverse transcription was performed using a Transcriptor First Strand cDNA Synthesis Kit (product no. 04379012001, Roche).

2.5 | Western blot analysis

Antibodies against HK2 (#2867), SQSTM1/p62 (#39749), and LC3A/B (#12741) were purchased from Cell Signaling Technology; tubulin (MS-581-P0) was purchased from NeoMarkers.
2.6 | Transient siRNA transfection

The following Silencer Select siRNAs were purchased from Applied Biosystems: siHIF1A (s6539), siEPAS1 (s4698), siHK2 #1 (s6560), and siHK2 #2 (s6562). Information on the siRNA sequence is listed in Table S1. Negative control siRNA (scrambled siRNA) was designed and synthesized by Nippon Gene. Transfection of siRNA was performed using Nucleofector II and the Cell Line Nucleofector Kit V (VCA-1003) (Amaxa) in accordance with the manufacturer’s protocol. The assay protocol has been described previously. In brief, cells were resuspended in nucleofector V solution, 100 μl cell suspension at a density of 1 × 10^7/mL was mixed with 1.0 μg siRNA, transferred to a cuvette and nucleofected using an Amara Nucleofector II apparatus with the S-020 program for MM.1S, the G-015 program for KMS-11, and the X-005 program for U266.

2.7 | Stable knockdown constructs and lentivirus infection

The HK2 Human shRNA Plasmid Kit (TL312415) including control plasmid was purchased from OriGene (Rockville). Information on shRNA sequences is listed in Table S1. Together with 9.0 μg ViraPower Packaging mix (Invitrogen), 3.0 μg of vectors were transfected using Lipofectamine 3000 (Invitrogen) into the 293FT producer cells. After overnight culture, the medium was exchanged to remove transfection reagents. Viral supernatants were harvested the following day, at 48-72 h after transfection. Then, 1 × 10^6 of KMS-11 cells were prepared with changed medium, and medium containing virus was added. After 3-d of culture, cells stably expressing siRNAs were sorted for GFP expression using a FACSia III instrument (BD Biosciences).

2.8 | ELISA assay

The CycLex Total p62 ELISA Kit (CY-7055) was purchased from Medical & Biological Laboratories and the Glycolysis Cell-Based Assay Kit (No. 600450) from Cayman Chemical. The assays were carried out in accordance with the manufacturer’s protocol.

2.9 | Autophagy detection on flow cytometry

DAPGreen-Autophagy Detection (D676) was purchased from Dojindo Molecular Technologies. DAPGreen (0.1 or 0.05 μmol/L)
was added after incubation of myeloma cells for 48 h under normoxic or hypoxic conditions. After a 1 h incubation, the double membranes of the autophagosome stained with the dye were assessed using a FACSCanto instrument (BD Biosciences).

### 2.10 Apoptosis assay

APC-Annexin V (550474), 7-AAD (559925), and Annexin V binding buffer (556454) were purchased from BD Biosciences. The assays were carried out as described previously using a FACSCanto instrument (BD Biosciences).²,¹⁰

### 2.11 Xenograft mouse model

KMS-11 cells (1 × 10⁶ each) were injected subcutaneously into the right or left side of the bodies of 6-8-wk-old female NOD/Shi-scid IL2rγnull (NOG) mice (Central Institute for Experimental Animals). The protocols for animal experimentation described in this paper were
approved by the Animal Committee, Akita University (approval no. a-1-3133).

2.12 | Reagents

3-Bromopyruvate (3-BrPA) (16490) was purchased from Sigma-Aldrich. Bortezomib (021-18901) was purchased from FUJIFILM Wako Pure Chemical. Recombinant human interleukin-6 (IL-6) (#8904SC) was purchased from Cell Signaling Technology. AZD8055 was purchased from ChemieTek.

2.13 | Statistical analysis

Student t test (Figures 2-6) and two-way ANOVA (Figure 5G) were used to test for significance. Bars represent the mean ± 95% confidence interval (CI) of 3 (Figures 2-6, except for Figure 4C) or 10 (Figure 4C) independent experiments. Asterisks (*) indicate statistical significance: *P ≤ .05; **P ≤ .01; ***P ≤ .001; NS, not significant.

3 | RESULTS

3.1 | Hypoxic stress induces autophagy in MM cells

Intracellular organelles related to autophagy include autophagosomes, lysosomes, and autolysosomes. Electron microscopy was performed to observe these organelles in patient samples (n = 2) and the myeloma cell line KMS-11, which were incubated under normoxic or hypoxic conditions (1% O₂) for 48 h. The number of organelles was markedly increased by hypoxia exposure (Figure 1A). To quantify autophagy activation in
We hypothesized that activation of autophagy under hypoxic conditions was induced by hypoxia-inducible genes in MM. To detect candidate gene(s) crucial to the acquisition of hypoxia-inducible autophagy in MM, we performed volcano plot analysis using our comprehensive gene expression data (GSE80545) obtained from patient samples (n = 4) that had been incubated under normoxic or hypoxic conditions (1% O₂) for 48 h. In total, the levels of 546 probes were elevated significantly under hypoxic conditions (fold change (FC) > 2.0, P < .05; Figure 2A). Gene Ontology (GO) analysis of these genes revealed that all top 10 categories were energy metabolism related (Figure 2B). Thirteen genes were associated with the "glycolytic process," including HK2, ENO2, ALDOC, PKFB3, HK2, PFKP, GPI, PGK1, LDHA, ALDOA, ENO1, PKM, and GAPDH (Figure 2C). Almost all of these genes were involved in
FIGURE 4 HK2 knockdown suppresses hypoxia-induced autophagy. A, Western blot analysis of LC3-I, LC3-II, and p62 for KMS-11 transiently transduced with siHK2 #1, siHK2 #2, and control scrambled siRNA (Scr) and cultured in normoxia or hypoxia (1% O_2) for 48 h (left panel). LC3-II/LC3-I ratio of the western blot analysis is also shown (right panel). B, ELISA assay of p62 for KMS-11 transiently transduced with siHK2 #1, siHK2 #2, and control scrambled siRNA (Scr) and cultured in normoxia or hypoxia (1% O_2) for 48 h. Bars represent mean ± 95% CI of 3 replicates. C, Photograph of electron microscopy for KMS-11 transiently transduced with siHK2 #1 or control scrambled siRNA (Scr) and cultured in normoxia or hypoxia (1% O_2) for 48 h (left panel). Count of autophagosome/cell and lysosome/cell of siHK2- or control-KMS-11 (n = 10 each) is also shown (right panel). D, Flow cytometry assay of autophagosome stained with DAPGreen for KMS-11 cell line cultured under hypoxia (1% O_2) for 48 h with or without AZD8055 (100 nmol/L, 6 h). y-axis: cell count, x-axis: autophagosome-FITC (left panel). Mean fluorescence intensity (MFI) of each samples are shown (right panel). E, Schematic illustrations of effects of hypoxic stress (black arrows), siHK2 (red arrows) and the mTOR inhibitor AZD8055 (blue arrows) on the HK2-mTORC1-autophagy axis. The left panel shows that hypoxia-inducible HK2 activates autophagy via mTORC1 inhibition, and the right panels shows that siHK2 inhibits autophagy and that the mTORC1 inhibitor AZD8055 activates autophagy. Asterisks indicate statistical significance: *0.01 ≤ P < .05; **0.001 ≤ P < .01; ***P < .001; NS, not significant.
glycolytic processes from glucose to the final metabolite product lactic acid (Figure 2D). Among these, an enzyme that metabolizes glucose to glucose-6-phosphate, hexokinase-2 (HK2), was included in the top 5 ($\log_2$ FC ratio > 2.0), and was located mostly upstream in glycolysis.\(^{24}\)

HK2 is involved in autophagy induction under stress conditions via inhibiting mTORC1,\(^{25,26}\) therefore we focused on the functions of HK2 under hypoxia in MM cells. HKs exist in 4 isoforms; our microarray data showed that only HK2 was elevated markedly in hypoxia-exposed patient samples and cell lines.
Results suggested that HK2 plays an important role in obtaining the anti-apoptotic phenotype of MM in hypoxic environments such as in the bone marrow microenvironment.

3.4 HK2 knockdown inhibits hypoxia-inducible autophagy in myeloma cells

We investigated whether HK2 controls autophagy against myeloma cells under hypoxic stress. Degradation of p62/SQSTM1 and an increased LC3-II/LC3-I ratio are considered useful for autophagy detection. Therefore, we conducted western blot analysis of p62 and LC3 against shHK2-KMS-11 and control-KMS-11 cells, which were cultured under normoxic or hypoxic conditions. Hypoxic stress decreased p62 expression and increased the ratio LC3-II/LC3-I in control-KMS-11 cells (Figure 4A). However, these changes were decreased by HK2 knockdown, suggesting that HK2 knockdown inhibited hypoxia-inducible autophagy. Furthermore, an ELISA assay to detect p62 revealed increased expression in shHK2-KMS-11 cells in hypoxic conditions, with no change under normoxic conditions (Figure 4B). We further conducted electron microscopy to confirm the accumulation of autophagosomes and lysosomes. Although we found increased autophagosome and lysosome formation in hypoxia-treated myeloma cells, the number of autophagosomes was significantly decreased in shHK2-KMS-11 cells (Figure 4C). These results suggested that HK2 is required for hypoxia-inducible autophagy in MM.

Next, we examined how HK2 regulates autophagy in a hypoxic environment. HK2 induces autophagy by inhibiting the activity of mTORC1 in normal murine tissues. The mTOR inhibitor AZD8055 induces autophagy in myeloma cells. We examined the effects of AZD8055 on autophagy in shHK2-KMS-11 or control-KMS-11 cells. As expected, flow cytometry analysis demonstrated that, under hypoxic conditions, AZD8055 treatment upregulated the fluorescence intensity of autophagosomes in control-KMS-11 cells, but had no significant effect on siHK2-KMS-11 cells compared with control cells (Figure 4D). Moreover, AZD8055 did not significantly upregulate the fluorescence intensity of autophagosomes in HK2 knockdown cells. This finding is consistent with the previous observation that HK2 regulates autophagy through inhibition of mTORC1. For a better understanding, these results are illustrated schematically in Figure 4E. Together, these data provide strong evidence that the HK2-mTORC1 pathway plays a key role in autophagy activation under hypoxic conditions.
3.5 | Cooperative effect of proteasome inhibitor on HK2-knocked down myeloma cells inoculated into NOG mice

Because both autophagy and proteasomal degradation play essential roles in the processing of misfolded proteins, simultaneous inhibition of their activities has been reported to cause strong ER stress, inducing cell death in myeloma cells. We examined the effect of cooperative inhibition of HK2 and proteasome. To determine the cooperative effects of both HK2 knockdown and PI in vivo, we established a stable HK2-knocked down KMS-11 cell line. Four sequences, shHK2 #A-#D, against KMS-11 cells were transfected using a lentiviral transfection system, and the knockdown effect of HK2 was examined by qRT-PCR and western blot analysis. shRNA #D markedly reduced HK2 mRNA and protein levels by 60% and 90%, respectively (Figure 5A,B). Constitutive HK2 inhibition by lentivirus has been reported to induce compensatory upregulation of HK1, resulting in the promotion of glycolysis in some solid cancer cell lines, therefore we examined the expression of other HK isoforms. There was no observation by qRT-PCR of a compensatory change in HK1 expression in shHK2-KMS-11 cells. HK3 and HK4 expression was not detected (Figure 5C), therefore the possibility of compensatory effects of other HKs was excluded in subsequent experiments.

As a preliminary experiment, 1 x 10^6 of control-KMS-11 or shHK2-KMS-11 cells were injected into immunodeficient mice (NOG mice) subcutaneously at day 0 (Figure S1), and the tumor was found to have become palpable from day 15. The tumor size in the shHK2 group tended to be smaller than that in the control group. Intraperitoneal administration of 1.0 mg/kg bortezomib appeared to exert a tumor-suppressive effect, although 0.2 mg/kg bortezomib showed no apparent anti-myeloma effects.

Based on this result, we injected 1 x 10^6 of control-KMS-11 or shHK2-KMS-11 cells subcutaneously into NOG mice at day 0 and later administered 1.0 mg/kg bortezomib or phosphate-buffered saline intraperitoneally every 4 d, starting on day 14 (Figure 5D). shHK2-KMS-11 xenografted mice treated with bortezomib showed significantly reduced tumor volumes; the percent inhibitions of control and shHK2 groups were 61% and 83%, respectively (Figure 5E). The mice were sacrificed and the tumors removed and weighed; the shHK2-KMS-11 xenografted mice treated with bortezomib showed significantly reduced tumor weights (Figure 5F,G). There was a positive correlation between the tumor volume calculated from the tumor size and measured tumor weight (Figure S2). Together, these results suggested that cooperative inhibition of HK2 and proteasome can further enhance their anti-myeloma effects in vivo.
3.6 | Apoptosis-inducible capability of HK2 inhibitor (3-BrPA) in hypoxia is greater than that in normoxia, and combination with bortezomib increased the effect

The HK2 inhibitor 3-BrPA induces apoptosis in myeloma cells and other cancer cells by suppressing ATP production and inhibiting drug efflux transporters.\(^{30-32}\) As HK2 knockdown increased apoptotic myeloma cells under hypoxic conditions (Figure 2), we hypothesized that its inhibitor 3-BrPA would also strongly induce apoptosis of myeloma cells under hypoxic stress. As expected, an apoptosis assay demonstrated that the numbers of 3-BrPA-treated viable cells under hypoxic conditions were significantly lower than those under normoxic conditions (Figure 6A). We further performed the same experiment using normal peripheral blood mononuclear cells (PBMC) and found no apparent differences between hypoxic and normoxic conditions, suggesting that 3-BrPA had greater effects on myeloma cells compared with normal cells under hypoxic conditions. These data indicated that HK2 inhibitors such as 3-BrPA are useful for treating myeloma cells adapted to the hypoxic microenvironment.

Finally, we evaluated the combined effects of 3-BrPA with bortezomib in vitro. Under normoxic conditions, administration of bortezomib alone or administration of 3-BrPA alone induced significantly greater cell death than in the control; combined administration further increased the number of apoptotic cells (Figure 6B). Importantly, both bortezomib and 3-BrPA administration under hypoxic conditions further increased apoptotic cells compared with under normoxic conditions. We conducted the same experiment using other myeloma cell lines (H929, MM.1S, and KMS-12-PE) and a PI-resistant patient sample and found that 3-BrPA enhanced the apoptotic effect of bortezomib (Figure 6C). Notably, 3-BrPA was also effective against a bortezomib-resistant patient sample that did not show apoptosis when treated with a high concentration of bortezomib (50 nmol/L). These results strongly suggested that an HK2 inhibition/inhibitor can induce apoptosis against PI-resistant myeloma cells.

4 | DISCUSSION

The average oxygen tension of human bone marrow aspirates is 52-56 mm Hg in both healthy control subjects and patients with MM.\(^{33}\) However, the endosteal niche, in which hematopoietic stem cells or “myeloma stem cells” are still present, is thought to have a much lower oxygen tension (~10 mm Hg) compared with other bone marrow regions.\(^{31,34,35}\) In hypoxic environments such as the bone marrow microenvironment, the transcription factor HIF is upregulated, leading to upregulation of HIF-dependent genes in myeloma cells.\(^{31}\) Thus, the gene expression pattern and phenotypes of myeloma cells in the bone marrow microenvironment may be distinct from those in other bone marrow regions. Several studies including this study have been conducted to detect the effects of hypoxic signals on myeloma cells. Numerous studies have also attempted to identify useful HIF inhibitors. However, because HIF moderates various essential genes involved in the survival of not only malignant cells but also normal cells, HIF inhibitors have not been applied practically to treat various cancers including MM. Therefore, inhibition of downstream genes of HIF is considered a therapeutic target. For instance, Mäso et al found that HIF-1α-inducible glycolytic enzymes including lactate dehydrogenase induced anti-apoptosis for myeloma cells.\(^{8}\) Recently, we also found that miR-210 and the H3K9 demethylase KDM3A were specifically upregulated in hypoxia-exposed myeloma cells. In hypoxia, the HIF-1α-miR-210 axis led myeloma cells to cellular quiescence via the suppression of IRF4, which is typically upregulated in MM and plays a crucial role in myeloma oncogenesis.\(^{9,10}\) Moreover, we found that the HIF-1α-KDM3A axis regulates glycolytic enzymes by upregulating the long non-coding RNA MALAT1, leading to the anti-apoptotic phenotype of MM.\(^{7}\) These findings indicated that glycolytic enzymes, but not oncogenes of MM such as IRF4, are important therapeutic targets for myeloma cells adapted to the hypoxic environment.

In the present study, we focused on the glycolytic gene HK2 among hypoxia-inducible factors. The glycolytic enzyme HK2 phosphorylates glucose to form glucose-6-phosphate in the first step of the glycolytic system and also plays an important role in tumorigenesis.\(^{26,37}\) HK has 4 isoforms: HK1, HK2, HK3, and HK4 (GCK).\(^{24}\) HK1 is expressed ubiquitously in various tissues; HK2 is expressed in insulin-sensitive tissues such as muscle and fat cells; HK3 is expressed in the lung and pancreas; and HK4 is expressed in the liver and pancreas. Among these HKs, HK2 is the most important isoform in various cancers.\(^{38-40}\) Several groups including our group have suggested the clinical significance of HK2 in MM. For instance, Rasche et al\(^{41}\) reported that HK2 expression was related to the positive rate of FDG-PET in MM. Moreover, Abe et al reported that low HK2 expression-related FDG-PET false-negative cases showed a good prognosis.\(^{42}\) These reports strongly suggested that aberrant HK2 overexpression is associated with a worse prognosis of patients with MM. Moreover, activation of HK2 may be oncogenic. However, in previous studies, samples were likely to have been obtained from a normoxic bone marrow blood rather than an hypoxic bone marrow microenvironment. No studies have precisely examined the role of HK2 in myeloma cells adapted to hypoxic stress.

Glycolytic enzymes are promising targets for cancer therapy.\(^{43}\) As HK2 is a critical enzyme that regulates the first step of glycolysis, we cannot completely rule out the possibility that apoptosis induction in HK2-knocked down myeloma cells was due to the inhibitory effect of glycolysis. Additionally, we found that HK2 knockdown suppressed the production of lactic acid, the final glycolytic metabolite, under both normoxic and hypoxic conditions. Even in an aerobic environment, glycolysis is activated in cancer cells, a phenomenon known as the Warburg effect. Nevertheless, in our study, HK2 knockdown induced apoptosis under hypoxic conditions, but not under normoxic conditions. Hence, our data strongly suggested that, in a hypoxic environment, HK2 contributes to apoptosis inhibition by other mechanism rather than glycolysis. This is in accordance
with a previous study that reported that HK2 exerts its cytoprotec-
tive effects by inducing not only glycolysis but also autophagy.26 Thus, our findings revealed an autophagy-inducing function of the
glycolytic factor, HK2, which is ectopically expressed under hypoxic conditions.

We found that HK2-inducible autophagy is “oncogenic” in MM, particularly in myeloma cells in the hypoxic bone marrow microenvi-
ronment. In other hematopoietic tumors, such as diffuse large B-cell
lymphoma, autophagy can also act as a tumor suppressor.44 In con-
trast, the oncogenic autophagy mechanism is likely to be myeloma
specific because, unlike other cancers, myeloma cells are exposed to
intense ER stress caused by large amounts of non-functional mono-
clonal proteins. Therefore, the survival of myeloma cells depends on
proteasomal protein degradation. Even when the proteasome was
inhibited by PIs, the activation of autophagy led myeloma cells to
acquire an apoptosis-resistant phenotype, as autophagy can also
reduce ER stress.13,28 Considering the importance of autophagy of
myeloma cells in the hypoxic environment,18,19 targeting the HK2-
autophagy axis is a promising therapeutic strategy (Figure 7A). The
development of a specific inhibitor of HK2 may improve the prog-
osis of patients with refractory MM. Indeed, Xu et al45 recently
demonstrated the effect of antisense oligos of HK2 against
myeloma xenografted mice. However, because inhibition of the gly-
colysis system is also likely to damage normal tissues, it may be nec-
essary to develop a drug delivery system that allows a HK2 inhibitor
to exert its effect only in the bone marrow microenvironment. The
development of a novel therapeutic strategy including a drug delivery
system to inhibit HK2 activity only under hypoxic conditions is
promising for refractory MM.

Because PIs compensatively activate autophagy, a better ther-
apeutic effect may be obtained by simultaneous inhibition of both
autophagy and the proteasome.22,28 Therefore, combinations of
autophagy-targeted drugs and PIs have been evaluated by several
groups.36,47 In our study, there was no apparent synergistic ef-
fect between HK2 inhibition and bortezomib in vitro and in vivo.
However, when we used bortezomib against shHK2 inoculated
mice, the mice showed the most anti-tumor effect. The anti-my-
eloma effect of PI under normoxia and that of HK2 inhibitor under
hypoxia may have led to complementary therapeutic effects against
myeloma cells. In fact, clinical trials of combination therapy with a
hypoxia-targeting drug evofosfamide (TH-302) and bortezomib (in a
Phase I/II trial) have been successfully conducted for refractory/
relapsed MM.48-50 Our results suggested that PIs and inhibitor of
hypoxia-inducible factors may be effective for each fraction with
different gene expression, but not for single fraction, leading to
complementary deep responses (Figure 7B).

In conclusion, our data indicated that hypoxia-inducible HK2
promotes autophagy and inhibits apoptosis in myeloma cells sub-
jected to hypoxic stress. These data also strongly suggest that a
combination of PIs (effective in the normoxic environment) and
HK2 inhibition (effective in the hypoxic environment) may com-
plementarily result in a greater response to treatment-resistant/
refractory MM.

ACKNOWLEDGMENTS
We thank Jyunseuke Yamashita, Yukiko Abe, Yoko Chiba, and Hiromi
Kataho for their outstanding technical assistance. This study was
supported by Nippon Shinyaku Research Grant (Nippon Shinyaku,
Kyoto, Japan) to SI.

DISCLOSURE
SI has received research funding from Nippon Shinyaku. NT received
honararia from Pfizer, Otsuka, and Novartis and research funding from
Novartis.

ORCID
Sho Ikeda https://orcid.org/0000-0002-3780-2993
Naoto Takahashi https://orcid.org/0000-0002-6758-3787

REFERENCES
1. Mateos MV, Ludwig H, Bazarbachi A, et al. Insights on multiple my-
eloma treatment strategies. Hemasphere. 2018;3:e163.
2. Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow mi-
croenvironment in multiple myeloma. Immунul Rev. 2015;263:160-172.
3. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. The role of hy-
poxia and exploitation of the hypoxic environment in hematologic
malignancies. Mol Cancer Res. 2014;12:1347-1354.
4. Gezer D, Vukovic M, Soga T, Pollard PJ, Kranc KR. Concise review:
genetic dissection of hypoxia signaling pathways in normal and leu-
kemic stem cells. Stem Cells. 2014;32:1390-1397.
5. Ri M. Endoplasmic-reticulum stress pathway-associated mecha-
nisms of action of proteasome inhibitors in multiple myeloma. Int J
Hematol. 2016;104(3):273-280.
6. Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple
myeloma. Cancer Treat Rev. 2018;70:199-208.
7. Ikeda S, Kitadate A, Abe F, Takahashi N, Tagawa H. Hypoxia-inducible
KDM3A addiction in multiple myeloma. Blood Adv. 2018;2:323-334.
8. Maiso P, Huynh D, Moschetta M, et al. Metabolic signature identi-
fies novel targets for drug resistance in multiple myeloma. Cancer
Res. 2015;75(10):2071-2082.
9. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple my-
eloma. Nature. 2008;454:226-231.
10. Ikeda S, Kitadate A, Abe F, et al. Hypoxia-inducible microRNA-210
regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Cancer Sci. 2017;108:641-652.
11. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. The
emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
Leukemia. 2011;25:1533-1542.
12. Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M.
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1
alpha in multiple myeloma. Transl Res. 2015;165:641-650.
13. Yun Z, Zhichao J, Hao Y, et al. Targeting autophagy in multiple my-
eloma. Leuk Res. 2017;59:97-104.
14. Desantis V, Saltarella I, Lamanuzzi A, et al. Autophagy: a new mech-
anism of prosurvival and drug resistance in multiple myeloma.
Transl Oncol. 2018;11:1350-1357.
15. Levine B, Kroemer G. Autophagy in the pathogenesis of disease.
Cell. 2008;132:27-42.
16. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat
Cell Biol. 2010;12:814-822.
17. Ohsumi Y. Historical landmarks of autophagy research. Cell Res.
2014;24:9-23.
18. Fang Y, Tan J, Zhang Q. Signaling pathways and mechanisms of
hypoxia-induced autophagy in the animal cells. Cell Biol Int.
2015;39:891-898.
19. Daskalaki I, Gikas I, Tavernarakis N. Hypoxia and selective autophagy in cancer development and therapy. Front Cell Dev Biol 2018;6:104.

20. Kimmelman AC, White E. Autophagy and tumor metabolism. Cell Metab. 2017;25:1037-1043.

21. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014;74:647-651.

22. Hoang B, Benavides A, Shi Y, Frost P, Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009;8:1974-1984.

23. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12:1-222.

24. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049-2057.

25. Roberts DJ, Tan-Sah VP, Ding EY, Smith JM, Miyamoto S. Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol Cell. 2014;53:521-533.

26. Tan VP, Miyamoto S. HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy. 2015;11:963-964.

27. Cirstea D, Santo L, Hideshima T, et al. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther. 2014;13:2489-2500.

28. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102:8567-8572.

29. Kudryavtseva AV, Fedorova MS, Zhavoronkov A, et al. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells. BMC Genet. 2016;17(Suppl 3):156.

30. Nakano A, Tsuji D, Miki H, et al. Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. J Bioenerg Biomembr. 2012;44:31-38.

31. Majkowski-Skrobek G, Augustyniak D, Lis P, et al. Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. Anticancer Drugs. 2014;25:673-682.

32. Colla S, Storti P, Donofrio G, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24:1967-1970.

33. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA. 2007;104:5431-5436.

34. Lévesque JP, Winkler IG, Hendy J, et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells. 2007;25:1954-1965.

35. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001;276:43407-43412.

36. Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213-228.

37. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the anti-apoptotic effects of growth factors and Akt. Oncogene. 2006;25:4683-4696.

38. Shinohara Y, Ichihara J, Terada H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Lett. 1991;291:55-57.

39. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem. 1995;270:16918-16925.

40. Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30-34.

41. Abe Y, Ikeda S, Kitadate A, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345-1350.

42. Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511.

43. Li M, Chiang YL, Lyssiotis CA, et al. Non-oncogene addiction to SIRT3 plays a critical role in lymphomagenesis. Cancer Cell. 2019;35:916-931.

44. Xu S, Zhou T, Doh HM, et al. An HK2 antisense oligonucleotide induces synthetic lethality in HK1-HK2+ multiple myeloma. Cancer Res. 2019;79:2748-2760.

45. Mishima Y, Santo L, Eda H, et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015;169:423-434.

46. Jarauta V, Jaime P, Gonzalez O, et al. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo. Cancer Lett. 2016;382:1-10.

47. Laubach JP, Liu CJ, Raje NS, et al. A phase I/II study of evofosfamide, a hypoxia-activated prodrug with or without bortezomib in subjects with relapsed/refractory multiple myeloma. Clin Cancer Res. 2019;25:478-486.

48. Halbert JS, Rimsdorfer J, Van Valkenborgh E, et al. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol. 2016;77:441-457.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.